Sandbox Reserved 1613: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
These two domains contain the active site of this transporter protein. The interest in this protein is in its involvement with mutidrug resistant cancer cells. This involvement is due to its active site's promiscuity as many xenobiotics have been found to transported to the outside of the cell by this transporter. | These two domains contain the active site of this transporter protein. The interest in this protein is in its involvement with mutidrug resistant cancer cells. This involvement is due to its active site's promiscuity as many xenobiotics have been found to transported to the outside of the cell by this transporter. | ||
==Function== | ==Function== | ||
==Disease== | == Disease == | ||
==Relevance== | Multidrug resistant cancers are due to ABCG2 excreting cancer drugs out of the cell before they have the chance to kill the cell. Some of these cancers include breast, ovarian, and lung. | ||
== Relevance == | |||
Due to ABCG2 excreting xenobiotics from the cell, they also transport essential cancer drugs out of the cell. By utilizing certain inhibitors (5D3 and MZ29), it is possible to shut down these transporters in order to get cancer drugs to remain in and apoptosis the cell. However, this could have residual effects on the excretory system as ABCG2 would no longer be able to excrete anything from the cell, including those detrimental to the body. | |||
==Structural Highlights== | ==Structural Highlights== | ||
</StructureSection> | </StructureSection> | ||
